However, high CRLF2 levels and increased activation of JAK2 sufficiently activate wild-type KRAS in 80% of DL-ALL cases, suggesting that therapeutics inhibiting overstimulated KRAS are needed [17]. The gene discussed is KRAS; the disease is acute lymphoblastic leukemia.